J&J’s Velcade Is Not Cost-Effective For Multiple Myeloma, U.K.’s NICE Suggests
This article was originally published in The Pink Sheet Daily
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.
You may also be interested in...
Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.